mProX™ Human SSTR3 Stable Cell Line

Product Information

Target Protein

SSTR3

Target Family

Somatostatin Family

Target Protein Species

Human

Host Cell Type

U2OS; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

CNS Research

Related Diseases

Vipoma; Hydrolethalus Syndrome

Gene ID

6753

UniProt ID

P32745

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SSTR3 (Somatostatin Receptor 3) is a protein that the SSTR3 gene in humans codes for. A member of the family of somatostatin receptor proteins is encoded by SSTR3. This receptor has seven transmembrane (TM) segments that bridge alpha helices, seven transmembrane (TM) segments, an extracellular C-terminal, an intracellular N-terminal, and amino acid residues ranging from 362 to 428. Pituitary adenoma and oncogenic are two disorders that SSTR3 is linked to. The growth of tumor cells is inhibited by somatostatin, which has also been demonstrated in recent research to limit angiogenesis, the growth and proliferation of blood vessels. The SSTR3 receptor subtype inhibits angiogenesis by blocking the activities of endothelial nitric oxide synthase (eNOS) and MAPK. The customized SSTR3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Lindsay

We are quite happy with the knockdown cells that you made. Sep 11 2022

chat Verified Customer

chat Harriet

I have confirmed in our lab that the cells have work. Jun 09 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 SSTR phosphorylation of SSTRs in HEK293 cells.

SSTR3 is phosphorylated in HEK293 cells with ITF2984 specificity. HEK293 cells that were transiently transfected with HA-SSTR3 were treated for 5 minutes at 37 °C with 10 M SST-14, Octreotide, Pasireotide, or ITF2984. After being lysed, cells were immunoblotted using the phosphosite-specific antibodies that were listed.

Ref: Modena, Daniela, et al. "Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas." Cancers 15.13 (2023): 3453.

Pubmed: 37444563

DOI: 10.3390/cancers15133453

Research Highlights

In a mouse model of glucose excursion, the imidazolyl-tetrahydro-β-carboline class of sstr3 antagonists showed effectiveness and may have therapeutic potential for type 2 diabetes. The oral, telemetrized cardiovascular (CV) pups that were tested with the initial candidate in this class experienced unacceptable QTc interval prolongation.
Shah, Shrenik K., et al. "Discovery of MK-1421, a potent, selective sstr3 antagonist, as a development candidate for type 2 diabetes." ACS Medicinal Chemistry Letters 6.5 (2015): 513-517.
Pubmed: 26005524 DOI: 10.1021/ml500514w

These results imply that the function of somatostatin analogue therapy, whether radiolabeled or not, should be reevaluated in light of the underlying SDHB immunohistochemical pattern.
Elston, Marianne S., et al. "Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas." Human pathology 46.3 (2015): 390-396.
Pubmed: 25554089 DOI: 10.1016/j.humpath.2014.11.012